Abstract: Objective To study the safety and efficacy of atorvastatin in elderly patients with CAD when combined with substrates and inhibitors of CYP3A4, so as to find out the risk factors associated with atorvastatin-induced myopathy. Methods The clinical data of elderly patients, who had received atorvastatin, were collected in one research center from March to June in 2017 and analyzed by SPSS. The associated risk factors were analyzed by multivariate linear regression analysis. Results There was no significant effect on the safety and efficacy of atorvastatin for elderly patients with CAD, combined with the inhibitors of CYP3A4. However, with the increasing number of the substrates of CYP3A4, CRE showed a rising tendency. According to the result of multivariate linear regression analysis, CK could be influenced by age, gender, dyslipidemia, and the inhibitors of CYP3A4 in elderly patients with CAD. Conclusion The safety parameters should be monitored when elderly patients received atorvastatin and in combination with CYP3A4 inhibitors and multiple CYP3A4 substrates, especially the CRE and CK.

Key words: atorvastatin, drug-drug interaction, CYP3A4, safety, efficacy, myopathy